Foundry Partners LLC cut its stake in shares of Prestige Consumer Healthcare Inc (NYSE:PBH) by 4.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,999 shares of the company’s stock after selling 535 shares during the period. Foundry Partners LLC’s holdings in Prestige Consumer Healthcare were worth $403,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in PBH. Citizens Financial Group Inc RI acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $25,000. Huntington National Bank raised its position in shares of Prestige Consumer Healthcare by 45.4% during the first quarter. Huntington National Bank now owns 782 shares of the company’s stock worth $29,000 after purchasing an additional 244 shares during the period. Chevy Chase Trust Holdings Inc. acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $68,000. Islay Capital Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $85,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Prestige Consumer Healthcare by 48.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,458 shares of the company’s stock worth $100,000 after purchasing an additional 801 shares during the period.
PBH has been the topic of a number of recent analyst reports. ValuEngine lowered Prestige Consumer Healthcare from a “hold” rating to a “sell” rating in a research report on Friday, May 1st. BMO Capital Markets upped their price target on Prestige Consumer Healthcare from $85.00 to $91.00 and gave the company a “market perform” rating in a research report on Tuesday, May 12th. CIBC upped their price target on Prestige Consumer Healthcare from $86.00 to $88.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Jefferies Financial Group lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, April 14th. Finally, TD Securities lowered Prestige Consumer Healthcare to a “hold” rating and set a $86.00 price target on the stock. in a research report on Tuesday, April 14th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company’s stock. Prestige Consumer Healthcare presently has a consensus rating of “Hold” and an average price target of $66.17.
In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 29,593 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $40.00, for a total value of $1,183,720.00. Following the transaction, the chief executive officer now owns 154,630 shares in the company, valued at $6,185,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.14% of the company’s stock.
Shares of NYSE PBH opened at $42.18 on Friday. The business’s 50-day moving average price is $39.65 and its two-hundred day moving average price is $39.04. The company has a debt-to-equity ratio of 1.50, a current ratio of 2.44 and a quick ratio of 1.67. Prestige Consumer Healthcare Inc has a one year low of $27.40 and a one year high of $46.12. The company has a market capitalization of $2.07 billion, a P/E ratio of 13.99, a price-to-earnings-growth ratio of 3.46 and a beta of 0.80.
Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, May 7th. The company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.08. Prestige Consumer Healthcare had a return on equity of 13.33% and a net margin of 14.77%. The firm had revenue of $251.20 million for the quarter, compared to the consensus estimate of $239.65 million. During the same quarter in the previous year, the company posted $0.72 earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc will post 2.99 EPS for the current year.
Prestige Consumer Healthcare Company Profile
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.
Further Reading: What is the Current Ratio?
Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc (NYSE:PBH).
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.